Close Menu

Admit it -- you've probably at least considered buying Illumina stock since the company announced its acquisition of Solexa. Motley Fool has an article on Illumina's earnings with a quick analysis of the company's numbers and position in the competitive landscape. One interesting tidbit the story points out: "its bottom line was eroded by $8.7 million" thanks to the eagerness with which employees have been cashing in their stock options.

 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Australia will not be regulating gene editing of plants, animals, and human cell lines as long as no new genetic material is incorporated, reports Nature News.

The Washington Post reports that the US Department of Agriculture told its researchers to label peer-reviewed articles as "preliminary" work.

Researchers have sequenced the genomes of both the coast redwood and the giant sequoia, according to the San Francisco Chronicle.

In PNAS this week: study of epigenetic patterns in mammalian eggs, clonal expansion patterns in CD8+ T cells, and more.